| Title | Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19 |
| Authors | Gao, Suyu Yang, Qingqing Wang, Xuanxuan Hu, Wen Lu, Yun Yang, Kun Jiang, Qiaoli Li, Wenjing Song, Haibo Sun, Feng Cheng, Hong |
| Affiliation | Wuhan Univ, Zhongnan Hosp, Dept Pharm, Wuhan, Peoples R China Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing, Peoples R China Natl Med Prod Adm, Key Lab Res & Evaluat Pharmacovigilance, Beijing, Peoples R China Chinese Soc Toxicol, Beijing, Peoples R China |
| Keywords | POPULATION FAILURE MECHANISM |
| Issue Date | 21-Mar-2022 |
| Publisher | FRONTIERS IN PHARMACOLOGY |
| Abstract | The outbreak of coronavirus disease 2019 (COVID-19) has led to the emergence of global health care. In this study, we aimed to explore the association between drug treatments and the incidence of drug-induced liver injury (DILI) in hospitalized patients with COVID-19. A retrospective study was conducted on 5113 COVID-19 patients in Hubei province, among which 395 incurred liver injury. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards models. The results showed that COVID-19 patients who received antibiotics (HR 1.97, 95% CI: 1.55-2.51, p < 0.001), antifungal agents (HR 3.10, 95% CI: 1.93-4.99, p < 0.001) and corticosteroids (HR 2.31, 95% CI: 1.80-2.96, p < 0.001) had a higher risk of DILI compared to non-users. Special attention was given to the use of parenteral nutrition (HR 1.82, 95% CI: 1.31-2.52, p < 0.001) and enteral nutrition (HR 2.71, 95% CI: 1.98-3.71, p < 0.001), which were the risk factors for liver injury. In conclusion, this study suggests that the development of DILI in hospitalized patients with COVID-19 needs to be closely monitored, and the above-mentioned drug treatments may contribute to the risk of DILI. |
| URI | http://hdl.handle.net/20.500.11897/642058 |
| DOI | 10.3389/fphar.2022.799338 |
| Indexed | SCI(E) |
| Appears in Collections: | 公共卫生学院 |
